These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8254500)

  • 21. Muramyl Tripeptide-Phosphatidyl Ethanolamine Encapsulated in Liposomes (L-MTP-PE) in the Treatment of Osteosarcoma.
    Meyers PA
    Adv Exp Med Biol; 2020; 1257():133-139. PubMed ID: 32483736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes.
    Fogler WE; Fidler IJ
    Int J Immunopharmacol; 1987; 9(2):141-50. PubMed ID: 3583507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state.
    Sone S; Utsugi T; Tandon P; Ogawara M
    Cancer Immunol Immunother; 1986; 22(3):191-6. PubMed ID: 3731204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
    Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
    J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
    Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
    J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liposome-encapsulated MTP-PE: a novel biologic agent for cancer therapy.
    Asano T; Kleinerman ES
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):286-92. PubMed ID: 8280710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liposomal MTP-PE for the adjuvant therapy of osteosarcoma.
    Kleinerman ES; Jaffe N
    Prog Clin Biol Res; 1990; 343():263-79. PubMed ID: 2198583
    [No Abstract]   [Full Text] [Related]  

  • 28. Pre- and postirradiation hemopoietic effects of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) administered to C57Bl/6 mice before irradiation.
    Macková NO; Fedorocko P
    Neoplasma; 1993; 40(6):379-85. PubMed ID: 8289971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MTP-PE in liposomes as a biological response modifier in the treatment of cancer: current status.
    Frost H
    Biotherapy; 1992; 4(3):199-204. PubMed ID: 1599803
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update.
    Gianan MA; Kleinerman ES
    Cancer Biother Radiopharm; 1998 Oct; 13(5):363-8. PubMed ID: 10851426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Functional characteristics of the rat liver macrophage population after a single intravenous injection of liposome-encapsulated muramyl peptides.
    Hoedemakers RM; Vossebeld PJ; Daemen T; Scherphof GL
    J Immunother Emphasis Tumor Immunol; 1993 May; 13(4):252-60. PubMed ID: 8334109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The lipophilic muramyl peptide MTP-PE is a potent inhibitor of HIV replication in macrophages.
    Lazdins JK; Woods-Cook K; Walker M; Alteri E
    AIDS Res Hum Retroviruses; 1990 Oct; 6(10):1157-61. PubMed ID: 1701314
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.
    Vail DM; MacEwen EG; Kurzman ID; Dubielzig RR; Helfand SC; Kisseberth WC; London CA; Obradovich JE; Madewell BR; Rodriguez CO
    Clin Cancer Res; 1995 Oct; 1(10):1165-70. PubMed ID: 9815908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
    Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
    J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Administration of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and diclofenac in the combination attenuates their anti-tumor activities.
    Fedorocko P; Hoferová Z; Hofer M; Brezáni P
    Neoplasma; 2003; 50(3):176-84. PubMed ID: 12937850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
    Chou AJ; Kleinerman ES; Krailo MD; Chen Z; Betcher DL; Healey JH; Conrad EU; Nieder ML; Weiner MA; Wells RJ; Womer RB; Meyers PA;
    Cancer; 2009 Nov; 115(22):5339-48. PubMed ID: 19637348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct chemiluminescence immunoassay (CLIA) for muramyl tripeptide phosphatidyl-ethanolamine in plasma.
    Gay B; Towbin H; Schnell C; Einsle K; Graf P; Gygax D
    J Biolumin Chemilumin; 1991; 6(2):73-80. PubMed ID: 1882709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse effects at adjuvant treatment of liver metastases in rat with RSU-1069 + microspheres, or liposomal MTP-PE.
    Wang L; Roos G; Stenram U
    Anticancer Res; 1995; 15(5B):2077-80. PubMed ID: 8572605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.
    Fidler IJ; Fogler WE; Brownbill AF; Schumann G
    J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regional muramyl tripeptide phosphatidylethanolamine administration enhances hepatic immune function and tumor surveillance.
    Karpoff HM; Jarnagin W; Delman K; Fong Y
    Surgery; 2000 Aug; 128(2):213-8. PubMed ID: 10922994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.